Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-03-03A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma
-
CLINICAL_TRIALS study record update · 2025-02-27Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention
-
CLINICAL_TRIALS study record update · 2025-02-27A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection
-
CLINICAL_TRIALS study record update · 2025-02-27A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2025-02-24Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-02-21NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Therapy
-
CLINICAL_TRIALS study record update · 2025-02-20Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
-
CLINICAL_TRIALS study record update · 2025-02-18A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-02-17BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
-
CLINICAL_TRIALS study record update · 2025-02-17A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
-
CLINICAL_TRIALS study record update · 2025-02-13An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
-
CLINICAL_TRIALS study record update · 2025-02-13Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
-
CLINICAL_TRIALS study record update · 2025-02-11Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
-
CLINICAL_TRIALS study record update · 2025-02-10A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)
-
CLINICAL_TRIALS study record update · 2025-02-05A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
-
CLINICAL_TRIALS study record update · 2025-02-03A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
-
CLINICAL_TRIALS study record update · 2025-02-03Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
-
CLINICAL_TRIALS study record update · 2025-02-03A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
-
CLINICAL_TRIALS study record update · 2025-01-29A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-01-28Phase II Randomized Study Evaluating a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer
-
CLINICAL_TRIALS study record update · 2025-01-24A Prospective Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma in Australia
-
CLINICAL_TRIALS study record update · 2025-01-23Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma
-
CLINICAL_TRIALS study record update · 2025-01-22Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
-
CLINICAL_TRIALS study record update · 2025-01-22An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2025-01-15A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)